• PDF / 174,796 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 95 Downloads / 159 Views

DOWNLOAD

REPORT

---

1 S

DRESS syndrome and lack of efficacy: 2 case reports In a case series, a 48-year-old woman and a 39-year-old women were described, who developed drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome during treatment with brentuximab vedotin for cutaneous T-cell lymphoma [route and dosage not stated]; additionally, the women experienced lack of efficacy during treatment with interferon and methotrexate, respectively. Case 1: The 48-year-old woman with large-cell transformed CD30+ cutaneous T-cell lymphoma presented with fever and influenza like symptoms. She had a new rash on her trunk and face 3 days after her 3rd cycle of brentuximab vedotin. She had been initiated on brentuximab vedotin 45 days before presentation, as she was unresponsive to interferon, phototherapy and total-skin electron-beam radiotherapy. Preceding the 1st cycle of brentuximab vedotin, her course was complicated with several admission due to fungaemia, bacteraemia and Staphylococcus haemolyticus bacteraemia, which was treated with doxycycline and levofloxacin 23 days before the 1st cycle. On evaluation, she had multiple small, pink, flesh colored and hyperpigmented papules without umbilication or ulceration scattered over the trunk and face, and right-sided cervical lymphadenopathy. Additionally, poikilodermatous, unchanged eroded, scaly plaques consistent with cutaneous T-cell lymphoma were observed. Her lab tests revealed eosinophilia 0.59 x 103/µL, elevated aminotransferase with aspartate aminotransferase 229 U/L, alanine aminotransferase 179 U/L and creatinine 1.31 mg/dL. Punch biopsy of the left side of the neck demonstrated vacuolar-interface dermatitis. DRESS syndrome was suspected due to new-onset eosinophilia, fever, new exanthem morphology with vacuolar interface alteration and hepatocellular injury. However, due to rapid recovery of the symptoms and unclear causative agent, she received 4th cycle of brentuximab vedotin with 50% reduction in dose and dexamethasone pre-medication. After one month and 6 days of the 4th cycle, she was hospitalised with recurrence of symptoms, including exanthema and fever. During first 2 days of the admission, her lab test revealed eosinophilia 0.46 to 0.83 x 103/µL, aspartate aminotransferase 46 to 75 U/L, alanine aminotransferase 38 to 75 U/L and creatinine 1.02 to 1.23 mg/dL. She was diagnosed with brentuximab vedotin induced DRESS syndrome. She was treated with methylprednisolone [solumedrol] followed by tapering prednisone once her laboratory abnormalities resolved. Case 2: The 39-year-old woman with stage IIIa CD301 folliculotropic cutaneous T-cell lymphoma (T4N0B0) presented with fever and painful swelling of her hands and legs, which spread to include her trunk, neck and face. Ten days before the onset of her symptoms, she was started on brentuximab vedotin for cutaneous T-cell lymphoma. Before initiation of brentuximab vedotin, she had experienced treatment failure with methotrexate, total-skin electron-beam radiotherapy and phototherapy. On evaluation, she had fever 39.7°C